The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis

Watanabe, Naohiro; Matsuda, Emiko; Masuda, Akiko; Nariai, Koichi; Shibasaki, Toshiaki

doi:10.1016/j.intimp.2003.10.009

Cited by 15 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cimetidine (an H 2 receptor blocker) and fexofenadine (an H 1 receptor blocker) were administered by addition to the drinking water of NOD mice from 6 weeks of age to study endpoint at 25 weeks of age at concentrations used by prior investigators [28; 29]. …”

Section: Resultsmentioning

confidence: 99%

Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice

Hübner

Larson

Torrero

et al. 2011

Clinical Immunology

View full text Add to dashboard Cite

Mounting evidence suggests that helminth infections protect against autoimmune diseases. As helminths cause chronic IgE-mediated activation of basophils and mast cells we hypothesized that continuous activation of these cells could prevents diabetes onset in nonobese diabetic (NOD) mice in the absence of infection. Anti-FcεR1 activated basophils and mast cells and resulted in the release of IL-4 and histamine into the bloodstream. Anti-FcεR1-treated NOD mice showed a type 2 shift in insulin-specific antibody production and exhibited significant delays in diabetes onset. IL-4 responses played a partial role as the protective effect of anti-FcεR1 therapy was diminished in IL-4-deficient NOD mice. In contrast, histamine signaling was not required as anti-FcεR1-mediated protection was not reduced in mice treated with histamine receptor blockers. These results demonstrate that anti-FcεR1 therapy delays diabetes onset in NOD mice and suggest that chronic basophil and mast cell activation may represent a new avenue of therapy for Th1-associated autoimmune diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice

Hübner

Larson

Torrero

et al. 2011

Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…Another parameter classically used to estimate the gravity of anaphylaxis after allergen provocation is body temperature change [22]. Therefore, the rectal temperature was monitored before and 1 h after the OVA challenge.…”

Section: Methodsmentioning

confidence: 99%

Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis

Román

Irache²,

Gómez³

et al. 2009

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Two major drawbacks of current subcutaneous specific immunotherapy are the risk to induce severe anaphylactic reactions and the need of multiple injections of the allergen to reduce IgE-mediated hypersensitivity. The sustained release of allergens over time provided by poly(lactide-co-glycolide) microparticles (MP) could mimic the current therapeutic schedule and decrease their allergenicity. Moreover, MP could also co-deliver Th1 immunoadjuvants, such as CpG motifs. Methods: Ovalbumin (OVA)-sensitized BALB/c mice were treated intradermally with OVA or OVA plus CpG containing MP. OVA-specific IgG1 and IgG2a as well as IgE total levels and cytokine production were assessed throughout the experiment. The protection exerted by the MP against allergen challenge was estimated with body temperature changes, mortality and other symptoms. Results: Microparticulated treatments, irrespective of the presence of CpG motifs, elicited a lower IgE/IgG2a ratio than those induced by the allergen in solution (free or with adjuvants). However, after induction of the anaphylactic shock, only mice treated with MP co-encapsulating OVA plus CpG showed a significant lower decrease in body temperature and were totally protected from death. Mice that were injected with OVA plus CpG in solution or with Alum displayed a marked fall of temperature accompanied by high mortality rates (70–100%). Conclusion: MP encapsulating both OVA, as an allergen model, and CpG sequences, as a pro-Th1 adjuvant, decreased the risk for OVA sensitization (IgE induction) and protected sensitized mice from anaphylactic shock after allergen provocation. Therefore, the combination of allergens and CpG sequences into MP could perform a safer alternative to current specific immunotherapy.

show abstract

“…The body temperature changes associated with anaphylactic shock were monitored by measuring the rectal temperature [28] without general anesthesia before and 10 min after the challenge. Anaphylactic symptoms (activity, bristly hair, and cyanosis) were evaluated 30 min after the challenge using a scoring system modified from previous reports [29,30].…”

Section: Evaluation Of Anaphylaxismentioning

confidence: 99%

Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis

Gómez

Gamazo

Román

et al. 2008

European Journal of Pharmaceutics and Biopharmaceutics

View full text Add to dashboard Cite

Background: Specific immunotherapy implies certain drawbacks which could be minimized by the use of good adjuvants, capable of amplifying the appropriate immune response with minimal adverse effects.Objective: To evaluate the adjuvant capacity of the association of the rough lipopolysaccharide of Brucella ovis with Gantrez ® AN nanoparticles.Methods: Ovalbumin (allergen model)-containing Gantrez ® AN nanoparticles with either encapsulated or coated lipopolysaccharide were prepared and administered intradermally to BALB/c mice in order to evaluate the immune response. Pre-sensitized BALB/c mice were also administered with the formulations and they were challenged with an intraperitoneal injection of ovalbumin. Anaphylactic symptoms, including mortality rates, were evaluated after the challenge.

show abstract

The effects of fexofenadine on eosinophilia and systemic anaphylaxis in mice infected with Trichinella spiralis

Cited by 15 publications

References 23 publications

Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice

Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice

Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis

Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis

Contact Info

Product

Resources

About